The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

Johnson & Johnson (J&J) announced data from the phase 3 ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at ...

A Phase 2b/3, randomised, double-blind, placebo-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ...

Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 Technology appraisal guidance TBC Guselkumab for treating moderately to severely active ulcerative colitis ID6237 ...